New developments in treatment of ovarian carcinoma: Focus on trabectedin

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 233-242

  Cassier, Philippe A ^a   Duret, Aude ^a   Trédan, Olivier ^a   Carrabin, Nicolas ^b   Méeus, Pierre ^b   Treilleux, Isabelle ^c   Guastalla, Jean Paul ^a   Ray Coquard, Isabelle ^a,d  

^a Département de Medecine   (France)

^b Départements de Chirurgie Cardio Thoracique   (France)

^c CENTRE LÉON BÉRARD   (France)

^d UNIVERSITÉ DE LYON   (France)

Author keywords

Chemotherapy; Combination; DNA repair; Drug development; Ovarian cancer

Indexed keywords

BEVACIZUMAB; BIBF 1120; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; OLAPARIB; PACLITAXEL; PAZOPANIB; TRABECTEDIN;

ADVANCED CANCER; ALOPECIA; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; COLORECTAL CANCER; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROECTODERM TUMOR; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; REVIEW; SEPSIS; SIDE EFFECT; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 78049432092     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/CMR.S9459     Document Type: Review

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Guerin S, Doyon F, Hill C. The frequency of cancer in France in 2006, mortality trends since 1950, incidence trends since 1980 and analysis of the discrepancies between these trends. Bull Cancer. 2009;96:51-57. French.
3. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351: 2519-2529.
4. Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A. Systemic therapy in recurrent ovarian cancer: Current treatment options and new drugs. Expert Rev Anticancer Ther. 2010;10:81-88.
5. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinumbased chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-2106.
6. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An Intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24: 4699-4707.
7. Pujade-Lauraine E, Wagner U, Avall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323-3329.
8. Pfisterer J, Vergote I, du BA, Eisenhauer E. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15 Suppl 1:36-41.
9. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
10. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004; 95:1-8.
11. Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol. 2007;64:129-138.
12. Cannistra SA. Evaluating new regimens in recurrent ovarian cancer: How much evidence is good enough? J Clin Oncol. 2010; 28:3101-103.
13. David-Cordonnier MH, Gajate C, Olmea O, et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol. 2005;12:1201-1210.
14. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001;7:961-966.
15. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin- 743 inhibits activated but not constitutive transcription. Cancer Res. 2002;62:3377-3381.
16. Valoti G, Nicoletti MI, Pellegrino A, et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res. 1998;4:1977-1983.
17. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol. 1999;10:1233-1240.
18. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Crosstalk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006;66:8155-8162.
19. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res. 2001;7:185-191.
20. Sessa C, de Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol. 2005;20:1867-1874.
21. Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007;97:1618-1624.
22. Del Campo JM, Roszak A, Bidzinski M, et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol. 2009;20:1794-1802.
23. McMeekin S, del Campo JM, Colombo N, et al. Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies. ASCO Meeting Abstracts 2007 Jun 20;25(18 Suppl):5579.
24. Morgan JA, Le Cesne A, Chawla S, et al. Randomized Phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I). [abstract] J Clin Oncol. 2007;25 Suppl 18S:10060.
25. Mutch DG, Orlando M, Goss T, et al. Randomized Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811-2818.
26. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;20;26:890-896.
27. Blay JY, von Mehren M, Samuels BL, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res. 2008;14:6656-6662.
28. Sessa C, Cresta S, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer. 2009;45:2116-2122.
29. von Mehren M, Schilder RJ, Cheng JD, et al. A Phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008;19:1802-1809.
30. Messersmith WA, Jimeno A, Ettinger D, et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008;63:181-188.
31. von Mehren M, Buck D, Temmer E, Elsayed YA, Cohen RB. Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies. J Clin Oncol. 2006;24 Suppl 18S:2068.
32. Chu Q, Mita A, Forouzesh B, et al. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res. 2010;16:2656-2665.
33. Gore L, Rivera E, Lavallee K, et al. Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies. J Clin Oncol. 2006;24 Suppl 18S:2079.
34. Vidal L, Garcia-Martin M, Tan S, et al. Phase I combination study of trabectedin and carboplatin in patients with advanced solid tumors. Ann Oncol. 2010;15 Suppl 3:iii102-1.
35. Monk BJ, Sill M, Walker JL, et al. Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A Phase II study of the Gynecologic Oncology Group (GOG). J Clin Oncol. 2010; 28 Suppl 15:5046.
36. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010; 28:3107-3114.
37. Poveda A, Tjulandin S, Kong B, et al. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr + PLD) versus PLD alone: Results from a PPS cohort of a phase III study. J Clin Oncol. 2010;28 Suppl 15:5012.
38. Poveda A, Kaye SB, Herzog T, et al. Correlation of RNA expression of DNA repair genes with clinical outcomes of advanced ovarian cancer (OC) pts treated with pegylated liposomal doxorubicin (PLD) vs trabectedin (T) + PLD in the ET743-OVA-301 clinical trial. Eur J Cancer Suppl. 2009;7:451.
39. Weberpals J, Garbuio K, O'Brien A, et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer. 2009;124:806-815.
40. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27:5601-5606.
41. Ledermann JA, Rustin GJ, Hackshaw A, et al. A randomized Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol. 2009;27 Suppl 15S:5501.
42. Friedlander M, Hancock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a Phase II study. J Clin Oncol. 2007;25 Suppl 18S:5561.
43. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913-917.
44. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
45. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-134.
46. Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumors that will respond to PARP inhibitors? A Phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol. 2010;28 Suppl 15S:3002.
47. Fong PC, Yap TA, Boss DS, et al. Poly (ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28:2512-2519.
48. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331-1338.